Myeloid neoplasms (AML/MDS)

Clinical trials for Myeloid neoplasms (AML/MDS) explained in plain language.

Never miss a new study

Get alerted when new Myeloid neoplasms (AML/MDS) trials appear

Sign up with your email to follow new studies for Myeloid neoplasms (AML/MDS), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Trials to join now! 1

Engineered immune cells take aim at Hard-to-Treat cancers

Disease control Recruiting now

This early-stage study tests a new treatment called NT-175 for people with advanced solid tumors (like lung, colon, or breast cancer) that have a specific mutation (TP53 R175H) and a certain immune marker (HLA-A*02:01). NT-175 is made from a patient's own immune cells, which are …

Matched conditions: MYELOID NEOPLASMS (AML/MDS)

Phase 1 • Sponsor: AstraZeneca • Aim: Disease control

Last updated Sep 03, 2026 00:00 UTC

Myeloid neoplasms (AML/MDS)

Get alerted when new Myeloid neoplasms (AML/MDS) trials appear

Engineered immune cells take aim at Hard-to-Treat cancers